OpenBilldrug price receipt

NADAC week of 2026-10-14

ETHOSUXIMIDE 250 MG CAPSULE

For 30 capsules

Pharmacies pay

$7.30 filed

30 × $0.24349 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.


The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$13.40 estimated

$7.30 + $1.10 (15%) + $5.00 fee per fill = $13.40

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ETHOSUXIMIDE 250 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ethosuximide.

FDA gives its dosage form as “capsule” and “capsule, liquid filled” and its route as oral.

FDA lists 4 labelers (the companies named on the label) for its NDCs, among them Epic Pharma, LLC, Chartwell RX, LLC and Strides Pharma Science Limited.

FDA’s Established Pharmacologic Class for it is Anti-epileptic Agent.

The NADAC file of 2026-10-14 prices it under 5 NDCs (National Drug Codes); the FDA directory lists 4 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $7.30 for 30 capsules (30 × $0.24349 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

All 5 NDCs

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name ethosuximide with ETHOSUXIMIDE 250 MG CAPSULE.

ProductPharmacies pay per unitMedicare per unit
ETHOSUXIMIDE 250 MG CAPSULE this page
generic · capsule / capsule, liquid filled
$0.24349 per EA filed
eff. 2026-09-23
We don’t know yet
ETHOSUXIMIDE 250 MG/5 ML SOLN
generic · solution
$0.10045 per ML filed
eff. 2026-09-23
We don’t know yet
ZARONTIN 250 MG CAPSULE
brand · capsule
$1.30857 per EA filed
eff. 2026-01-01
$1.13247 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 5 NDCs’ NADAC prices is $0.24349 per EA filed.

Of the 85 other products in FDA’s Anti-epileptic Agent class priced per EA, 56 have a higher middle NADAC price and 29 a lower one. The one in the middle is PHENYTEK 200 MG CAPSULE, at $1.4026 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

We don’t know yet; the card above says why.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.